Ellen Rosenberg - 27 Apr 2026 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Reporting relationship: Chief Legal Officer
Issuer ticker: FOLD
Reported as of: 27 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Apr 2026, 16:38:32 UTC
Prior SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Christian Formica, Attorney-in-Fact

Key filing fact

Ellen Rosenberg filed Form 4 for AMICUS THERAPEUTICS, INC. (FOLD) on 27 Apr 2026.

Key facts

This page summarizes Ellen Rosenberg's Form 4 filing for AMICUS THERAPEUTICS, INC. (FOLD).
8 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 27 Apr 2026, 16:38.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001666380 Primary reporting owner

Rosenberg Ellen

Relationship: Chief Legal Officer
Address: 47 HULFISH STREET, PRINCETON
Signature: /s/ Christian Formica, Attorney-in-Fact
Signature date: 27 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FOLD transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -463,898
Change %: -100%
Price: $14.50^*
Shares after: 0
Date: 27 Apr 2026
Ownership: Direct
Footnotes: F1

FOLD transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -15,000
Change %: -100%
Price: $14.50^*
Shares after: 0
Date: 27 Apr 2026
Ownership: By Spouse
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FOLD transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value
Shares: -93,663
Change %: -100%
Price
Shares after: 0
Date: 27 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 93,663
Exercise price: $10.04
Footnotes: F3, F4

FOLD transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value
Shares: -107,575
Change %: -100%
Price
Shares after: 0
Date: 27 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 107,575
Exercise price: $9.55
Footnotes: F3, F4

FOLD transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value
Shares: -134,044
Change %: -100%
Price
Shares after: 0
Date: 27 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 134,044
Exercise price: $12.11
Footnotes: F3, F4

FOLD transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value
Shares: -138,008
Change %: -100%
Price
Shares after: 0
Date: 27 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 138,008
Exercise price: $11.93
Footnotes: F3, F5

FOLD transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value
Shares: -108,980
Change %: -100%
Price
Shares after: 0
Date: 27 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 108,980
Exercise price: $14.24
Footnotes: F3, F5

FOLD transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value
Shares: -203,825
Change %: -100%
Price
Shares after: 0
Date: 27 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 203,825
Exercise price: $9.41
Footnotes: F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Ellen Rosenberg is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 5 footnotes

Footnote F1

The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 311,410 shares of Common Stock and 152,488 restricted stock units (which vested in full in connection with consummation of the Merger).

Footnote F2

The reported securities were disposed of in connection with the consummation of the Merger, which included 15,000 shares of Common Stock.

Footnote F3

In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.

Footnote F4

Each Option was fully vested.

Footnote F5

Each Option vested in full in connection with consummation of the Merger.